Positron emitting radionuclide labeled peptides for human upar pet imaging
AssigneeCurasight Aps
InventorsAndreas KJAER, Morten PERSSON, Jacob MADSEN
Life of this patent
Estimating the term…
Abstract
There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Claims11
A positron-emitting radionuclide labelled peptide conjugate for use in the prediction/diagnosis of aggressiveness, prognosis, progression or recurrence by PET imaging of uPAR expressing tumors, said conjugate comprising a uPAR binding peptide coupled via a chelating agent, such as DOTA, NOTA, CB-TE2A or NODAGA, or covalently to a radionuclide selected from 18F, 64Cu, 68Ga, 66Ga, 60Cu, 61Cu, 62Cu, 89Zr, 124I, 76Br, 86Y, and 94mTc, wherein the conjugate is to be administered in a dose of 100-500 MBq followed by PET scanning ½-24 h after the conjugate has been administered, and quantification through SUVmax and/or SUVmean.
Dependencies are inferred from the claim text.